Altshuler Shaham Ltd acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 246 shares of the medical research company’s stock, valued at approximately $39,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. RMR Wealth Builders purchased a new stake in shares of IQVIA in the second quarter worth $25,000. Shine Investment Advisory Services Inc. purchased a new stake in shares of IQVIA in the second quarter worth $35,000. Old North State Trust LLC purchased a new stake in shares of IQVIA in the third quarter worth $40,000. Carroll Financial Associates Inc. increased its stake in shares of IQVIA by 36.4% in the third quarter. Carroll Financial Associates Inc. now owns 322 shares of the medical research company’s stock worth $50,000 after purchasing an additional 86 shares in the last quarter. Finally, Community Bank N.A. boosted its position in shares of IQVIA by 341.0% during the second quarter. Community Bank N.A. now owns 441 shares of the medical research company’s stock worth $63,000 after acquiring an additional 341 shares during the last quarter. 88.65% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently weighed in on IQV shares. TheStreet upgraded shares of IQVIA from a “c” rating to a “b” rating in a research report on Tuesday, October 20th. Deutsche Bank Aktiengesellschaft upped their target price on shares of IQVIA from $180.00 to $196.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Zacks Investment Research lowered shares of IQVIA from a “buy” rating to a “hold” rating and set a $163.00 target price for the company. in a research report on Tuesday, September 22nd. Morgan Stanley upped their target price on shares of IQVIA from $182.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 21st. Finally, UBS Group upped their target price on shares of IQVIA from $204.00 to $224.00 and gave the stock a “buy” rating in a research report on Wednesday, October 21st. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $172.78.

In other news, insider Ari Bousbib sold 69,120 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $170.00, for a total value of $11,750,400.00. Following the completion of the sale, the insider now owns 721,155 shares in the company, valued at approximately $122,596,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.00% of the stock is currently owned by company insiders.

IQVIA stock opened at $169.77 on Friday. The firm has a 50-day moving average price of $165.25 and a 200-day moving average price of $154.08. The firm has a market capitalization of $32.55 billion, a PE ratio of 186.56, a price-to-earnings-growth ratio of 2.65 and a beta of 1.45. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 2.00. IQVIA Holdings Inc. has a 12-month low of $81.79 and a 12-month high of $180.77.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 20th. The medical research company reported $1.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.52 by $0.11. The firm had revenue of $2.79 billion during the quarter, compared to analyst estimates of $2.75 billion. IQVIA had a net margin of 1.61% and a return on equity of 18.03%. The business’s revenue was up .6% on a year-over-year basis. During the same quarter last year, the business earned $1.60 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 5.85 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.